Cargando…
On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial
BACKGROUND: Camrelizumab plus chemotherapy significantly prolonged progression-free survival (PFS) and overall survival (OS) compared to chemotherapy alone as first-line treatment in advanced lung squamous cell carcinoma (LUSC) in the phase III trial (CameL-sq), which has become an option of standar...
Autores principales: | Jiang, Tao, Chen, Jianhua, Xu, Xingxiang, Cheng, Ying, Chen, Gongyan, Pan, Yueyin, Fang, Yong, Wang, Qiming, Huang, Yunchao, Yao, Wenxiu, Wang, Rui, Li, Xingya, Zhang, Wei, Zhang, Yanjun, Hu, Sheng, Guo, Renhua, Shi, Jianhua, Wang, Zhiwu, Cao, Peiguo, Wang, Donglin, Fang, Jian, Luo, Hui, Geng, Yi, Xing, Chunyan, Lv, Dongqing, Zhang, Yiping, Yu, Junyan, Cang, Shundong, Zhang, Yaxi, Zhang, Jiao, Yang, Zeyu, Shi, Wei, Zou, Jianjun, Zhou, Caicun, Ren, Shengxiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722280/ https://www.ncbi.nlm.nih.gov/pubmed/34980131 http://dx.doi.org/10.1186/s12943-021-01479-4 |
Ejemplares similares
-
Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer
por: Gao, Guanghui, et al.
Publicado: (2022) -
Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial
por: Ren, Shengxiang, et al.
Publicado: (2022) -
Efficacy and safety of camrelizumab plus apatinib in previously treated patients with advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration
por: Gao, Guanghui, et al.
Publicado: (2022) -
Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non‐small‐cell lung cancer characterizes the features of response to PD‐1 blockade plus chemotherapy
por: Wu, Fengying, et al.
Publicado: (2022) -
Open the Technical Black Box of Tumor Mutational Burden (TMB): Factors Affecting Harmonization and Standardization of Panel-Based TMB
por: Sung, Meng-Ta, et al.
Publicado: (2022)